Who will win Covid-19 vaccine race?

Who will win Covid-19 vaccine race?

2020-10-13 • Updated

What happened?

Goldman Sachs claimed that vaccine developments tend to have more impact on the overall sentiment than even election results or Q3 earnings. We have had already a chance to observe how recent negative news weighed on the market sentiment. Johnson & Johnson announced that it has temporarily stopped the Covid-19 vaccine trials because of the unexplained illness of one participant. As a result, the market sentiment deteriorated, and the safe-haven US dollar rose today. However, the nature of the illness hasn’t been yet defined: a special committee is trying to find it out.

Actually, it has been the second-largest setback in the vaccine race so far. AstraZeneca halted human trials for a similar reason: a patient had an adverse reaction. Trials have been resumed in the UK, Brazil, India, and South Africa, while it remains on hold in the US as the Food and Drug Administration has been still investigating that case.

High-potential companies

Both AstraZeneca and Johnson & Johnson have created adenovirus-based vaccines. So, perhaps, biotech companies, which use other technologies will have a boost. For instance, Moderna is working on a vaccine, based on the technique of using messenger ribonucleic acid (mRNA). It is said that this technique has more advantages than traditional drug development by medical and manufacturing reasons.

By the way, BioNTech uses the same mRNA technique. Pfizer and BioNTech are creating the vaccine in collaboration, and two companies have announced that their vaccine has been accepted for a rolling review by Health Canada. It looks like Pfizer and BioNTech have all chances to win this rally. Don’t you think?

Forecasts from Goldman Sachs

Goldman Sachs gives the 71% of probability that the vaccine will be available for widespread distribution by the first quarter of 2021. Notably, the bank upgraded its forecasts from 39%, which it gave in August. Elsewhere, Goldman wrote in a note to its clients that it expects strong growth in such sectors as healthcare, consumer staples, and information tech companies. At the same time, the energy and industrials sectors are predicted to slump.

Technical tips

Pfizer is edging higher. It approaches the intersection of the 200-week moving average and the strong resistance level of $37.25, which it has failed to break in previous years. That’ why we can expect some sell-off around this area. Once the breakout happens, it will encourage buyers, and the price may surge to the recent high of $39.00. On the flip side, there is a 7-months support line which constrains the price to fall beyond. The move below September’s dips of $36.00 will push the price lower to the next support of $34.00.


Just look at great BioNTech’s performance. In comparison with other biotech giants as Pfizer, it’s a young company, but it has managed to rise enormously so far. BioNTech made its US stock market initial public offering last October 15, and it increased its value so much that it has been included in Nasdaq. The move above March’s high of $95.00 will drive the price to the record high of $105.00. Support levels are $76.00 and 70.00.


What should you do for trading BioNTech and Pfizer?

Trading stocks with FBS is easy. Follow the simple steps described below.

  1. First of all, be sure you’ve downloaded Metatrader 5. FBS allows you to trade stocks only through this software.
  2. Open the MT5 account in your personal area.
  3. Reveal all trading instruments by clicking “show all” at the “Market Watch” window.
  4. Start trading!



WTI and Brent React To a Key Pivot
WTI and Brent React To a Key Pivot

Brent oil is currently on a bullish trend, facing resistance near $84 and supported by the 200-day EMA. Breaking above this level could lead to a climb towards $90. Short-term support is observed around $80, backed by the 50-day EMA. As summer approaches and travel increases, crude oil tends to benefit from seasonal patterns. Despite temporary setbacks, buying...

XBRUSD: Prepares to Correct Intraday Rally
XBRUSD: Prepares to Correct Intraday Rally

Bearish Scenario: Sales below 80.00 with TP1: 79.34, TP2: 78.94, TP3: 78.55, and 78.00 Bullish Scenario: Buys above 78.00 (wait for a retracement to the zone) with TP: 79.34 TP2: 80.00, and TP3: 81.00

Latest news

What To Trade In March
What To Trade In March

The month of February saw markets make several instinctive moves as well as create opportunities for proper leveraging of fundamental releases. Despite being a leap-year, there wasn’t any real impact on price delivery in the course of the month. As we await the opportunities that lie ahead in the month of March, here are a few thoughts to consider.

CHF: Key Zone Could Yield Strong Reactions
CHF: Key Zone Could Yield Strong Reactions

USD/CHF saw a rebound after declining for two days straight, climbing towards the important psychological level of 0.8800 during Wednesday's early Asian trading session. There's some pressure on the Swiss Franc (CHF) as traders await the Swiss ZEW Survey – Expectations report scheduled for later today. Moreover, investors are keeping...

USD Expected To Recover Some Strength
USD Expected To Recover Some Strength

In the early hours of Tuesday, the US Dollar faces challenges in maintaining its strength against major currencies, with the US Dollar Index struggling to surpass the 104.00 mark. Investors are eagerly anticipating the release of key economic data, including January Durable Goods Orders and the Conference Board's Consumer Confidence Index for February. Additionally, the economic calendar includes reports...

Deposit with your local payment systems

Data collection notice

FBS maintains a record of your data to run this website. By pressing the “Accept” button, you agree to our Privacy policy.


A manager will call you shortly.

Change number

Your request is accepted.

A manager will call you shortly.

Next callback request for this phone number
will be available in

If you have an urgent issue please contact us via
Live chat

Internal error. Please try again later

Don’t waste your time – keep track of how NFP affects the US dollar and profit!

You are using an older version of your browser.

Update it to the latest version or try another one for a safer, more comfortable and productive trading experience.

Safari Chrome Firefox Opera